BioVersys Study Shows BV100 Lung Fluid Levels Reach 35 Times Plasma Concentrations

PUBT · 2d ago
BioVersys Study Shows BV100 Lung Fluid Levels Reach 35 Times Plasma Concentrations
  • BioVersys announced publication of two Phase 1 studies of BV100 on October 20, 2026, supporting its development for severe drug-resistant pneumonia.
  • Published results showed strong lung penetration, a milder drug-interaction profile than rifampicin and good tolerability in healthy participants.
  • The ongoing Phase 3 RIV-TARGET trial targets hospital- and ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter, with topline results expected in early 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioversys AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2418376_en) on October 20, 2026, and is solely responsible for the information contained therein.